A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
Authors
Ramon Espaillat
Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
Mar Llamas‐Velasco (ORCID: https://orcid.org/0000-0002-1187-1341)
Leonidas Drogaris
Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
Ramon Espaillat, Robert Bissonnette, Mark Lebwohl, Mar Llamas‐Velasco et al.
Citations
5 citations
Journal
Journal of the American Academy of Dermatology
Topics
Psoriasis: Treatment and Pathogenesis
Field-Weighted Citation Impact (FWCI)
1.20
article
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
Ramon Espaillat, Robert Bissonnette, Mark Lebwohl, Mar Llamas‐Velasco, Leonidas Drogaris, Linda Stein Gold, Michael Bukhalo, Tianyu Zhan, Samuel Sanchez‐Rivera, Greg St. John, Brad Glick, Kevin Douglas, Anqi Pan
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of the American Academy of DermatologyVol. 91(6)
Institutions
Henry Ford Health System (US), University of Puerto Rico System (PR), AbbVie (United States) (US), Arlington Dermatology (US), Hospital Universitario de La Princesa (ES), Innovaderm (Canada) (CA), Icahn School of Medicine at Mount Sinai (US)